<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">Dyslipidaemia</z:e> is one of the major risk factors for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> in <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="23" ids="18059">Lipid</z:chebi> changes associated with <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> are attributed to increases in free fatty acid flux, secondary to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we have investigated the beneficial effects of swertiamarin on dyslipidaemic conditions associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in <z:chebi fb="1" ids="9288">streptozotocin</z:chebi>-induced type 2 diabetic rats </plain></SENT>
<SENT sid="3" pm="."><plain>Swertiamarin (50 mg/kg, i.p.) administered once a day for 6 weeks resulted in significant (p &lt; 0.001) reductions in serum <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, cholesterol and <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> levels in diabetic animals as compared with diabetic control animals </plain></SENT>
<SENT sid="4" pm="."><plain>Serum fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> was significantly (p &lt; 0.05) decreased, moreover, the insulin sensitivity index was significantly (p &lt; 0.05) increased in swertiamarin treated animals </plain></SENT>
<SENT sid="5" pm="."><plain>Overall the data suggest that swertiamarin has beneficial effects on diabetic associated complications such as <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> </plain></SENT>
</text></document>